UK Licensed & Regulated Pharmacy
MHRA Compliant Medication
Privacy Assured
Images Are For Illustration Purposes Only

Wegovy (Semaglutide Injection)

4.7 out of 5 on Trustpilot
From £122.99 In Stock
Only £122.99 per pen!
UK Licensed & Regulated Pharmacy
MHRA Compliant Medication
Privacy Assured
Images Are For Illustration Purposes Only
Other Options Include

Introduction to Wegovy

Wegovy has taken the country by storm and has quickly become one of the leading medications for weight loss in the UK. Wegovy is a UK-licensed pharmaceutical used to support significant and sustainable weight loss. This advanced prescription medication is specifically designed to help individuals reduce excess weight and maintain a healthy body composition. Clinical trials have demonstrated that, on average, adults using Wegovy achieve a weight loss of approximately 15% of their initial body weight (around 35 pounds) with the standard 2.4mg dose. More recent results from the STEP UP trial show that higher doses can lead to an average weight loss of about 21%, with some individuals losing 25% or more of their starting weight, offering even greater potential for improved health and confidence. New clinical trials (SELECT) conducted on Wegovy have shown a 20% reduction in major adverse cardiovascular events in patient populations. Furthermore Wegovy is unique in that it does not alter the effectiveness of birth control pills, allowing you to manage your weight without compromising your contraceptive protection. Wegovy has quickly gained recognition and become one of the leading weight loss medications in the UK.

Licenses and Approvals

Wegovy is one of the few medications granted a specific license for weight loss in the United Kingdom, distinguishing it from medications like Ozempic, which is primarily approved for the management of diabetes. Wegovy's UK licensing for weight loss highlights its efficacy in assisting individuals with their weight loss goals. In contrast, Ozempic, while globally approved for diabetes management, is primarily intended to improve glycaemic control. Wegovy's specialized license underscores its role as a dedicated and effective weight management solution, further supporting individuals in their journey toward improved health.

Benefits for Wegovy

Wegovy offers several key benefits for individuals seeking to achieve and maintain weight loss, including the following:

Expected Weight Loss

Clinical studies show that Wegovy helps individuals lose approximately 15% of their initial body weight, with one in three adults losing up to 46 pounds. This makes Wegovy an excellent option for those aiming to reduce weight and improve their overall health.

Appetite Control

Wegovy targets appetite-regulating centres in the brain, reducing cravings and helping to prevent overeating, which can contribute to sustainable weight loss.

Sustained Results

Wegovy promotes long-term weight management. Clinical trials indicate that those who continued using Wegovy maintained or furthered their weight loss progress.

Wegovy 7.2 mg is the highest available dose of semaglutide, approved for use in the UK. It has been developed for patients with obesity who need a stronger level of appetite control and enhanced weight loss results after reaching their maintenance dose.

Wegovy works by mimicking the GLP-1 hormone, helping to reduce appetite, calm food cravings, and slow digestion so you feel fuller for longer. When combined with a healthy diet and increased physical activity, Wegovy 7.2 mg has been shown in clinical trials to deliver significantly greater average weight loss compared to lower doses.

Clinical Results

In clinical trials, patients using Wegovy 7.2 mg achieved:

  • Average weight loss of up to 20.7% of body weight
  • Around 1 in 3 patients losing 25% or more of their starting weight
  • A consistent safety profile similar to existing Wegovy doses when used as prescribed

Who Is Wegovy 7.2 mg Suitable For?

Wegovy 7.2 mg is indicated for adults living with obesity. It is prescribed as an optional further step after a minimum of 4 weeks on the 2.4 mg once-weekly maintenance dose, for patients who would benefit from additional weight loss support.

How Wegovy 7.2 mg Is Taken

Wegovy 7.2 mg is taken once weekly using the dedicated 7.2 mg single dose pre-filled pen. This is a single-use device containing one pre-set 7.2 mg dose, with a built-in hidden needle — no needle changes are required. Simply remove the cap, press firmly against the skin, and hold until the yellow indicator bar stops moving (approximately 5–10 seconds). Each pack contains 4 pens, providing one month's supply.

Storing Wegovy 7.2 mg

The 7.2 mg single dose pre-filled pen should be stored in a refrigerator (2°C to 8°C). It may be kept unrefrigerated for up to 28 days at a temperature not above 30°C. Do not freeze. Discard if frozen or if left out of the refrigerator for more than 28 days.

How Are Wegovy and Mounjaro Different?

Mounjaro (tirzepatide) and Wegovy (semaglutide) are both injectable treatments used to support weight management, but they work in slightly different ways and may suit different patients. Wegovy is a GLP-1 receptor agonist, while Mounjaro targets both GLP-1 and GIP receptors, which may offer added benefits for some individuals. Both medications are taken once weekly and can be highly effective when combined with lifestyle changes. Choosing between them depends on factors such as treatment goals, side effect profile, availability, and individual response, which is why professional guidance is essential.

Feature Mounjaro Wegovy
Generic Name Tirzepatide Semaglutide
Mechanism Dual GLP-1 & GIP receptor agonist GLP-1 receptor agonist
Weight Loss Efficacy Mean weight loss over 72 weeks: 15% (5 mg), 19.5% (10 mg), 21% (15 mg); some variability Mean weight loss at 2.4 mg: ~15%; some patients lost more than 15%. Mean weight loss at 7.2mg: ~21% with around 1 in 3 patients losing 25% or more over 72 weeks with no early plateau
Cardiovascular Benefit Not fully established; currently under investigation Shown to reduce CV risk by ~20%
Dosing Frequency Once weekly Once weekly
Available Strengths 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg (7.2 mg upcoming)
Titration Gradual weekly increases to reach target dose Gradual weekly increases to reach target dose
Common Side Effects Nausea, vomiting, diarrhea, constipation, indigestion, headache Nausea, vomiting, diarrhea, constipation, indigestion, headache, dysasthesia ( reported with higher 7.2mg)
Price (UK Sept 2025) £133–£330 depending on strength; set to rise ~170% No anticipated price increase
Contraception Additional barrier method required on top of normal contraceptives No effect on oral contraceptives
Availability / Supply Widely available, no anticipated supply issues Widely available, no anticipated supply issues

Some patients may need to switch between Wegovy and Mounjaro, either because of supply challenges or personal preference. While there are no clinical trials that directly study switching from one to the other, the process can be managed safely with guidance from a healthcare professional.

A short break between treatments is usually recommended. Most patients benefit from a washout period of around 7–14 days before starting the new medication. This helps reduce the chance of overlapping side effects and gives the body time to adjust.

Since the right approach depends on factors such as your medical history, current dosage, and treatment goals, our clinical team carefully reviews each case to make sure the transition is smooth and that you begin on the correct dose.

The table below outlines a guide for patients moving from Mounjaro to Wegovy.

Mounjaro Dose Guide for Wegovy Switch
2.5mg 0.5mg
5mg 0.5mg
7.5mg 1mg
10mg 1mg
12.5mg 1.7mg
15mg 2.4mg

Wegovy is consistently priced lower than Mounjaro across all equivalent dosing levels, making it the more cost-effective option for most patients. While some individuals on lower doses of Mounjaro may still find the treatment manageable, those on higher doses often benefit from switching to Wegovy to help reduce costs while maintaining treatment effectiveness.

Wegovy Strength IQDoctor Wegovy Price (£) Mounjaro Strength Mounjaro Prices (£) after Sep 1st
0.25mg 122.99 2.5mg 174.99
0.5mg 127.99 5mg 194.99
1.0mg 127.99 7.5mg 244.99
1.7mg 173.99 10mg 274.99
2.4mg 193.99 12.5mg 294.99
7.2mg Coming soon 15mg 279.99

Precautions For Use Of Wegovy

Always consult with your healthcare provider before starting Wegovy to determine if it is the appropriate option for you and to discuss any potential risks or interactions with other medications.

Most individuals taking Wegovy experience mild side effects. The most common side effects include nausea, diarrhoea, vomiting, constipation, abdominal pain, headache, fatigue, upset stomach, dizziness, bloating, belching, gas, stomach flu, heartburn, and a runny nose or sore throat. Data from the STEPUP trials showed an increased incidence of dysaesthesia with the 7.2mg dose which largely precluded without need for treatment.

Wegovy may also cause serious side effects, including:

  • Pancreatitis (inflammation of the pancreas): If you experience severe, persistent abdominal pain, with or without vomiting, contact your healthcare provider immediately. The pain may radiate from the abdomen to the back.

  • Gallbladder problems: Wegovy may lead to gallbladder issues, including gallstones, some of which may require surgery. Contact your healthcare provider if you develop symptoms such as upper abdominal pain, fever, jaundice (yellowing of the skin or eyes), or clay-coloured stools.

  • Hypoglycaemia (low blood sugar): Individuals with type 2 diabetes, especially those taking medications such as sulfonylureas or insulin, may experience an increased risk of low blood sugar. This is both a common and potentially serious side effect. Talk to your healthcare provider about recognising and managing low blood sugar. Symptoms may include dizziness, blurred vision, anxiety, irritability, sweating, slurred speech, hunger, confusion, drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery. Be sure to check your blood sugar before and during treatment with Wegovy.

  • Kidney problems: In individuals with existing kidney issues, diarrhoea, nausea, and vomiting can lead to dehydration, worsening kidney function. It is important to stay hydrated to minimise this risk.

  • Serious allergic reactions: Discontinue use of Wegovy and seek immediate medical attention if you experience symptoms of a serious allergic reaction, such as swelling of the face, lips, tongue, or throat, difficulty breathing or swallowing, severe rash or itching, fainting, dizziness, or rapid heartbeat.

  • Vision changes in individuals with type 2 diabetes: Notify your healthcare provider if you experience any changes in vision while taking Wegovy.

  • Increased heart rate: Wegovy can cause an increased heart rate at rest. If you experience a racing or pounding heart lasting several minutes, inform your healthcare provider.

  • Mental health concerns (depression or thoughts of suicide): Pay close attention to any new or worsening mental health symptoms, such as changes in mood, behaviours, thoughts, or feelings. Contact your healthcare provider immediately if you experience any concerning changes.

Do not use Wegovy if you:

  • Have or have had a family history of medullary thyroid carcinoma (MTC), a type of thyroid cancer, or if you have a condition known as Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

  • Have had a serious allergic reaction to Semaglutide or any ingredient in Wegovy.

Before using Wegovy, inform your healthcare provider if you have any of the following conditions:

  • A history of pancreatic or kidney problems.

  • Type 2 diabetes with a history of diabetic retinopathy.

  • A history of depression, suicidal thoughts, or mental health issues.

  • Are pregnant or planning to become pregnant. Wegovy may harm an unborn baby, and you should stop using it at least 2 months before trying to conceive.

  • Are you breastfeeding or plan to breastfeed? As it is unknown whether Wegovy passes into breast milk.

Always consult your healthcare provider for the most personalised and accurate advice.

Order Journey — Step by Step

Note: Next Day Delivery is counted from the time your prescription is approved by our prescriber, not from when you place your order.

Online Questionnaire

Complete our secure medical questionnaire so our prescribers can confirm treatment is safe and suitable for you.

Order & Payment

Place your order and pay — payment is held securely while the prescriber reviews your case.

If it's not suitable you will receive a full refund.
Upload Images

Upload BMI images, a copy of your ID, and any additional evidence (if requested).

Check your spam/junk folder to avoid delays.
Prescriber Review

A qualified clinician reviews your questionnaire and images. Respond promptly to any follow-up requests to avoid delays.

Approval & Dispatch

Once approved, we aim to dispatch for next-day delivery. Orders approved after the cut-off will be sent the next working day.

At iQ Doctor, we take great care to ensure your Wegovy® pen arrives safely and in accordance with the latest manufacturer and MHRA guidance.

Read our latest update here.

What Should I Do First When The Wegovy Pen Arrives?

For best results, we recommend storing your pen in the fridge at 2°C–8°C until you are ready to use it.

To keep your medication in the best condition:

  • Store it in its original carton to protect it from light.
  • Do not freeze the pen. If it has been frozen, it should not be used.
  • Keep it away from direct heat sources and sunlight.

What If The Pen Feels At Room Temperature When It Arrives?

There is no need to be concerned if your Wegovy pen arrives at room temperature.

Under updated MHRA-approved guidance, Wegovy can be transported at temperatures of up to 30°C for up to 48 hours during delivery without affecting the quality of the medication.

How Long Can I Keep Using It For?

  • It can be stored at temperatures below 30°C for up to 6 weeks.
  • A standard Wegovy pen contains four weekly doses, meaning your treatment course will typically be completed well within this timeframe.
  • Store the pen away from direct sunlight and excessive heat.
  • Always replace the pen cap after use.
  • Never store the pen with a needle attached.

Questions About Your Delivery?

If you have any concerns about how your medication was delivered or stored, our clinical team is here to help. Please contact us before using your medication if you are unsure.

Wegovy Frequently Asked Questions

Everything you need to know about Wegovy

The brand name for semaglutide, Wegovy is a once-weekly injection used to support long-term, sustained weight management.Wegovy works by mimicking a natural gut hormone (GLP-1) that helps regulate appetite, making you feel fuller for longer and reducing overall food intake.
Wegovy (semaglutide) is a prescription medication for adults who are looking to lose weight and improve health outcomes related directly to obesity. It is generally recommended for:
  • Adults with obesity: Body Mass Index (BMI) of 30 or higher
  • Adults who are overweight: BMI of 27 or higher with at least one weight-related health condition, such as type 2 diabetes, high blood pressure, or high cholesterol
Although Wegovy is licensed for people younger than 18, our clinic only serves patients aged 18 to 75 years. This is because additional precautions are required when prescribing and monitoring medication as part of a distance-selling service.
  • Wegovy is a once-weekly injection in the tummy, thigh, or upper arm
  • The dose is started low and increased gradually to reduce side effects
  • It is used alongside a reduced-calorie diet and increased physical activity for best results
Clinical trials have shown that Wegovy offers a number of health benefits beyond weight loss alone:
  • Heart health — in the SELECT trial, people taking Wegovy had a 20% lower risk of serious heart events such as heart attack and stroke. Wegovy is now also approved to help reduce cardiovascular risk in eligible patients
  • Liver health — in the ESSENCE trial, nearly two thirds of patients taking Wegovy showed resolution of serious fatty liver disease (MASH) after 72 weeks, compared to around one third of those not taking it. Over a third also showed improvement in liver scarring of at least one stage
  • Fat loss over muscle loss — analysis from the STEP 1 trial found that the majority of weight lost on Wegovy was fat rather than muscle. Including regular strength or resistance exercise during treatment helps protect muscle mass further
Wegovy (semaglutide) acts on the GLP-1 receptor to support appetite suppression and weight management, and it is available at a more affordable price point. Mounjaro (tirzepatide) targets both the GLP-1 and GIP receptors, providing a dual mechanism of action for appetite control, though typically at a higher cost. Both are effective injectable options for weight management. Currently, Wegovy is the only treatment with published long-term cardiovascular outcome data.
Yes, many people can transition if supply issues or personal choice make Wegovy preferable to Mounjaro. There are no head-to-head “switch” trials, so the decision should be individualised. A healthcare professional will guide you on when to stop one and start the other. It is advisable that all patients take a minimum 7-14 day washout period before switching over from Wegovy to Mounjaro, or vice versa. There are many factors to consider when switching and our team of expert clinicians will review your order and ensure you start at the correct dose.
Not usually. Both medications help control appetite, but they work in slightly different ways. Some people may notice a temporary increase in hunger, especially if there’s a gap between treatments or if the starting dose of Wegovy is lower than what they were used to. This effect is often short-lived, and your healthcare provider can adjust your dose to help keep appetite under control.
Both Mounjaro and Wegovy are effective for weight management, but individual results vary. Clinical trials have shown average weight reductions of around 15–21% with Mounjaro (depending on dose) and about 15% with Wegovy at its full dose. In addition, Wegovy has published data showing a 20% reduction in cardiovascular risk.
Both Mounjaro and Wegovy are effective for weight management, but individual results vary. Clinical trials have shown average weight reductions of around 15–21% with Mounjaro (depending on dose) and about 15% with Wegovy at its full dose. In addition, Wegovy has published data showing a 20% reduction in cardiovascular risk.
The choice often depends on personal factors such as cost, availability, treatment goals, and how well you respond to the medication. If you’re stable and progressing on Mounjaro and cost is not a concern, continuing may be the best option. If affordability or access is an issue, Wegovy can be just as effective for many people. Clinical trial data provides useful benchmarks, but your individual response matters most. Your healthcare provider will guide your treatment plan, adjust your dosing, and monitor your progress to help you achieve safe and sustainable weight loss.
Possibly.Both Mounjaro and Wegovy can cause nausea, vomiting, diarrhea/constipation or other gastrointestinal (GI) effects, especially when starting or increasing the dose. Some people may notice similar side effects during the initial weeks after switching to Wegovy, this is because there may be residual effects of Mounjaro still taking effect in your body whilst a new loading phase of Wegovy is introduced. Our clinicians will try to tailor your dose of Wegovy to avoid these side effects as best as possible.
  • Starting at the lowest effective dose: Starting low is the best way to reduce GI side effects, but this has to be balanced with keeping your appetite at bay
  • Gradual dose titration, as guided by your healthcare provider, can reduce GI symptoms
  • Stay consistent: Side effects often lessen over time as your body adjusts
  • Speak to your clinician: Your clinician can provide strategies to manage discomfort and monitor your response to the new medication
Wegovy can be used long-term under the guidance of your healthcare provider. Clinical studies have shown that continued use of Wegovy helps maintain weight loss and provides additional benefits, such as reduced cardiovascular risk. There is no requirement to switch back to another medication unless your clinician determines it’s necessary due to side effects, changes in health status, or personal preferences.
Yes - After placing your order for Wegovy, your clinician will email you requesting additional documentation. You will need to upload BMI selfies and proof of your previous treatment, such as a dispensing label or an invoice dated within the last six weeks. If you are switching from another provider of Wegovy and your BMI is under 25, you may also be asked to provide evidence of your starting weight, which can be a letter from your previous healthcare provider. This information helps your clinician determine the correct dose and plan your transition safely and effectively.
No - Unlike Mounjaro, Wegovy does not interfere with hormonal or barrier contraceptives, so you can continue using your preferred method of birth control. It is important to maintain effective contraception if you are of childbearing potential, as weight-loss medications are generally not recommended during pregnancy. Always discuss any planned pregnancy with your healthcare provider before starting or continuing Wegovy.
Yes - new interim guidelines from the BMS provide specific recommendations for women taking GLP-1 medications like Mounjaro or Wegovy alongside HRT.
  • Oestrogen: Oral oestrogen tablets may be affected because GLP-1 medications can slow digestion and reduce absorption. Your GP managing your HRT may want to switch you to a transdermal route—such as patches, gels, or sprays applied to the skin. This ensures the hormone is absorbed directly into the bloodstream, bypassing the digestive system entirely.
  • Progesterone: For oral progesterone (e.g., Utrogestan), absorption may also be reduced when starting or increasing Mounjaro or Wegovy. Your GP may recommend doubling your oral progesterone dose for the first four weeks 4 weeks after initiation and for 4 weeks after each dose escalation to maintain adequate protection of the uterine lining. Alternatively, they may suggest switching to a non-oral form, such as a Mirena coil, which provides reliable, consistent local progesterone release directly where it’s needed.
Important:Never change your progesterone or oestrogen dose on your own. Always discuss any adjustments with your healthcare provider to ensure safety and effectiveness.
Based on UK list prices as of September 2025, Wegovy is cheaper than Mounjaro at all dose ranges. Mounjaro set prices have increased by around 170% as of September 1st 2025, Wegovy remains more affordable, making it a cost-effective alternative for many patients, particularly those on higher doses. At lower Mounjaro doses, some patients may still find it reasonable to stay on Mounjaro, but for those on higher doses, switching to Wegovy can help maintain treatment effectiveness while reducing financial burden.
Yes. If Wegovy isn’t well tolerated - due to side effects, insufficient weight loss, or other reasons - your healthcare provider can help you switch back to Mounjaro or explore other suitable weight-loss treatments. The transition will be carefully planned, including any necessary washout period, dose adjustments, and monitoring to ensure safety and effectiveness.

Wegovy 7.2 mg is the highest available dose of semaglutide, now approved and available in the UK. It is designed for adults living with obesity who have already been using the standard 2.4 mg maintenance dose for at least 4 weeks and would benefit from additional weight loss support.

In clinical trials, patients using Wegovy 7.2 mg achieved an average body weight loss of up to 20.7%, with around 1 in 3 patients losing 25% or more of their starting weight. The safety profile is consistent with existing Wegovy doses when used as prescribed.

Wegovy 7.2 mg is administered once weekly using the dedicated 7.2 mg single dose pre-filled pen, which contains a built-in hidden needle for straightforward self-injection. Each pack contains 4 pens, providing one month's supply.

As with all doses of Wegovy, it should be used alongside a reduced-calorie diet and increased physical activity. Your prescriber will advise whether the 7.2 mg dose is appropriate for you.

Wegovy 7.2 mg is now approved and available in the UK. It can be prescribed for eligible adults living with obesity who have been on the 2.4 mg maintenance dose for a minimum of 4 weeks and would benefit from additional weight loss support.

If you are already prescribed Wegovy and think you may be suitable for the 7.2 mg dose, speak to your prescriber who will be able to advise whether stepping up is appropriate for you.